Best Seller of high quality Bivalirudin CAS NO (128270-60-0) available in bulk

1. Introduction to Bivalirudin (128270-60-0):

Bivalirudin is a synthetic peptide anticoagulant medication used to prevent blood clot formation, particularly in patients undergoing percutaneous coronary intervention (PCI) procedures such as angioplasty and stent placement. It belongs to the class of direct thrombin inhibitors and offers several advantages over traditional anticoagulants, including a rapid onset of action, predictable pharmacokinetics, and reduced risk of bleeding complications.

2. Chemical Composition and Molecular Structure:

Bivalirudin is a synthetic peptide consisting of 20 amino acids derived from the natural protein hirudin, which is found in the saliva of medicinal leeches. The molecular structure of bivalirudin closely resembles that of hirudin's active site, enabling it to bind directly to thrombin and inhibit its activity. The molecular formula of bivalirudin is C98H138N24O33.

3. Mechanism of Action:

Bivalirudin exerts its anticoagulant effects by directly inhibiting thrombin, a key enzyme involved in the coagulation cascade. By binding to the active site of thrombin, bivalirudin prevents the conversion of fibrinogen to fibrin, thereby inhibiting the formation of blood clots. Unlike indirect thrombin inhibitors such as heparin, bivalirudin does not require antithrombin as a cofactor for its activity.

4. Indications for Use:

Bivalirudin is primarily indicated for anticoagulation during PCI procedures, where it is used to prevent thrombus formation on coronary stents and reduce the risk of ischemic events such as myocardial infarction and stent thrombosis. It is often preferred over other anticoagulants, such as unfractionated heparin, in patients at high risk of bleeding or with heparin-induced thrombocytopenia (HIT).

5. Pharmacokinetics and Administration:

Bivalirudin is administered intravenously as a bolus followed by a continuous infusion during PCI procedures. It has a relatively short half-life of approximately 25 minutes, allowing for rapid reversal of its anticoagulant effects if necessary. The dose of bivalirudin is adjusted based on patient characteristics such as body weight, renal function, and the desired level of anticoagulation.

6. Advantages and Clinical Benefits:

Bivalirudin offers several advantages over traditional anticoagulants in the setting of PCI, including a lower risk of bleeding complications, reduced need for platelet transfusions, and improved clinical outcomes. Its direct inhibition of thrombin without the requirement for antithrombin cofactor makes it particularly suitable for patients with HIT or those undergoing complex PCI procedures.

7. Safety Profile and Adverse Reactions:

While bivalirudin is generally well-tolerated, it is associated with a risk of bleeding, particularly at the site of vascular access or in patients with preexisting bleeding disorders. Other potential adverse reactions may include allergic reactions, hypotension, and infusion site reactions. Close monitoring of vital signs and coagulation parameters is essential during bivalirudin therapy.

8. Reversal Agents and Management of Bleeding:

In the event of bleeding complications or the need for urgent reversal of anticoagulation, several strategies may be employed, including the administration of procoagulant agents such as protamine sulfate or recombinant activated factor VII (rFVIIa). These agents can help neutralize the anticoagulant effects of bivalirudin and promote hemostasis in bleeding patients.

9. Clinical Guidelines and Recommendations:

Bivalirudin is recommended as a first-line anticoagulant for patients undergoing PCI, particularly those at high risk of bleeding or with HIT. Clinical practice guidelines advocate for the use of bivalirudin in preference to heparin-based regimens in certain patient populations, such as those undergoing primary PCI for ST-segment elevation myocardial infarction (STEMI).

10. Future Perspectives and Research Directions:

Continued research into the optimal use of bivalirudin, including dosing strategies, duration of therapy, and management of bleeding complications, remains an area of active investigation. Further studies are needed to elucidate the long-term clinical outcomes and safety profile of bivalirudin in various patient populations and clinical settings, with the goal of optimizing anticoagulant therapy and improving patient outcomes in the management of cardiovascular disease.